ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/aromatase-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/aromatase-inhibitor
19
trial(s) found.
NCT07492641
Advanced
Phase 3
Recruiting
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease (
KANDELA-302
)
CDK4/6 inhibitor
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT07369505
Advanced
Phase 1
Recruiting
A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane) (
SP-03-B101
)
aromatase inhibitor
mTORC1/mTORC2 inhibitor
Breast cancer
Clear cell renal cell carcinoma
Hepatocellular carcinoma
Neuroendocrine tumour
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07358377
Advanced
Phase 1
Recruiting
An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor (
HRS-6209-205
)
CDK4 selective inhibitor
aromatase inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2086 - Frenchs Forest - GenesisCare Frenchs Forest
2576 - Bowral - Southern Highlands Private Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT07174336
Advanced
Phase 3
Recruiting
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
PI3Kalpha inhibitor,mutant selective,kinase/helical domain
placebo
+ aromatase inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4032 - Chermside - The Prince Charles Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07085767
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (
OPERA-02
)
CDK4/6 inhibitor
aromatase inhibitor
complete estrogen receptor antagonist
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3168 - Clayton - Monash Medical Centre (TERMINATED)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07062965
Advanced
Phase 3
Recruiting
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy (
C4551002
)
KAT6A/B inhibitor
KAT6 inhibitor
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06790693
Advanced
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (
INAVO123
)
PI3K alpha inhibitor
aromatase inhibitor
placebo
Breast cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NA
NA
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
CDK4/6 inhibitor
pan-PI3K/mTORC1/mTORC2 inhibitor
+ aromatase inhibitor
Breast cancer
NOT HER2-positive breast cancer
NOT Triple-negative breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - ICON Cancer Care
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
+ aromatase inhibitor
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
NCT06120283
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (
BGB-43395-101
)
CDK4 selective inhibitor
+ aromatase inhibitor
Breast cancer
Cancer
HER2-negative breast cancer
HR-positive breast cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2576 - Bowral - Southern Highlands Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (COMPLETED)
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
+ aromatase inhibitor
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05867251
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (
AVZO-021-1001
)
CDK2 inhibitor
+ aromatase inhibitor
Breast cancer
Epithelial Ovarian Cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
NCT05827081
Curative
Phase 3
Recruiting
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) (
Adjuvant-WIDER
)
CDK4/6 inhibitor
+ aromatase inhibitor
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3168 - Clayton - Monash Medical Centre
NCT05774951
Curative
Phase 3
Recruiting
CAMBRIA-1
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
selective estrogen receptor degrader
selective estrogen receptor modulator
+ aromatase inhibitor
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)
VIC
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (WITHDRAWN)
NCT04606446
Advanced
Phase 2
Recruiting
A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (
KAT6
)
KAT6A/B inhibitor
KAT6 inhibitor
+ aromatase inhibitor
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Giredestrant
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
+ aromatase inhibitor
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP1/2 inhibitor
PARP1 inhibitor
PARP2 inhibitor
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ aromatase inhibitor
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12607000218493
Advanced
Phase 2
Recruiting
Phase II Study Evaluating Efficacy and Safety of Everolimus with Letrozole for Management of Advanced (unresectable or metastatic) Non Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Treatment
aromatase inhibitor
mTORC1 inhibitor
Non-small cell lung cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (19)
Recruitment Country and State
VIC (15)
NSW (14)
SA (10)
QLD (9)
WA (9)
NZ (3)
TAS (2)
NT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (11)
Trial Type
Advanced (16)
Curative (3)
Cancer Therapy Class
oestrogen axis
100%
ER
63%
CDK4
58%
CDK6
47%
CDK4 selective
26%
mTOR
21%
mTORC1
21%
PI3Kalpha
21%
mTORC2
11%
KAT6
11%
KAT6A
11%
PARP
11%
Trop2
11%
androgen axis
11%
VEGF
11%
PI3K
5%
PARP1-selective
5%
BRAF
5%
CRAF
5%
FAK
5%
MEK
5%
RAF
5%
CDK2
5%
GnRH
5%
ER
5%
AKT
5%
CD40
5%
ERBB2
5%
IL-6
5%
LIV1
5%
PD-1/PD-L1
5%
PD-L1
5%
AR
5%
CYP17A1
5%
HMG-CoA reductase
5%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
2109 - North Ryde - Macquarie University Hospital (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
3168 - Clayton - Monash Medical Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2139 - Concord - Concord Repatriation General Hospital (3)
2031 - Randwick - Prince of Wales Hospital (3)
2500 - Wollongong - Wollongong Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2576 - Bowral - Southern Highlands Private Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
3630 - Shepparton - Goulburn Valley Health (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3135 - Ringwood East - Maroondah Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4215 - Southport - ICON Cancer Care (2)
5000 - South Australia - GenesisCare St Andrews Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2170 - Liverpool - Liverpool Hospital (1)
6009 - Nedlands - One Clinical Research (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2086 - Frenchs Forest - GenesisCare Frenchs Forest (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
NA
2076 - Wahroonga - Sydney Adventist Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2217 - Kogarah - St George Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3066 - Epping - Northern Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5000 - Adelaide - Cancer Research SA (1)
5042 - Bedford Park - Flinders Medical Centre (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
3002 - East Melbourne - Epworth Freemasons (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Urogenital cancer
Breast adenocarcinoma
Gynaecological cancer
Ovarian cancer
HER2-negative breast cancer
HR-positive breast cancer
Epithelial Ovarian Cancer
Lung cancer
Male genital cancers
Non-small cell lung cancer
Prostate cancer
Respiratory tract cancer
Thoracic cancer
Clear cell renal cell carcinoma
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Kidney cancer
Neuroendocrine tumour
Upper gastrointestinal cancer
ER-positive breast cancer
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
Triple-negative breast cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Central nervous system cancer
Cervical cancer
Glioblastoma
Glioma
HPV-related cancer
HPV16-positive cancer
High-grade glioma
Malignant glioma
Neurological cancer
Viral-related cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy